耳鼻咽喉科・頭頸部外科90巻3号

2018年03月発行

特集 頭頸部癌に対する薬物療法—最新情報

頭頸部癌における導入化学療法

著者： 藤井博文¹

所属機関： ¹自治医科大学附属病院腫瘍センター臨床腫瘍科

ページ範囲：P.206 - P.211

POINT

●局所進行頭頸部癌に対する導入化学療法（induction chemotherapy：ICT）の目的は，切除可能例における喉頭温存と，切除不能例に対する予後の改善である。

●レジメンとしてはドセタキセル（TXT：T），シスプラチン（CDDP：P），フルオロウラシル（5-FU：F）の3剤を併用したTPFが標準治療となっている。

●ICT後の腫瘍縮小の状態により放射線治療（radiation therapy：RT）か手術（喉頭摘出）かを判断するchemoselectionの考え方が用いられている。

●ICT後の放射線治療については，RT単独，抗がん薬とRTとの併用，セツキシマブ（アービタックス^®/セツキシマブ：E/Cmab）とRTとの併用のいずれがよいかは明確になっていない。

参考文献

1）The Department of Veterans Affairs Laryngeal Cancer Study Group：Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324：1685-1690, 1991

2）Lefebvre JL, et al：Larynx preservation in pyriform sinus cancer：preliminary results of a European Organization for Research and Treatment of Cancer phase Ⅲ trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88：890-899, 1996

3）Lefebvre JL, et al：Larynx preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma：10- year results of EORTC trial 24891. Ann Oncol 23：2708-2714, 2012

4）Forastiere AA, et al：Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engle J Med 349：2091-2098, 2003

5）Forastiere AA, et al：Long-term results of RTOG 91-11：a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31：845-852, 2013

6）Hoffman HT, et al：Laryngeal cancer in the united states：changes in demographics, patterns of care, and survival. Laryngoscope 116（Supple. 111）：1-13, 2006

7）Vermorken JB, et al：Cisplatin, fluorouracil, and docetatxel in unresectableheadandneckcancer head and neck cancer. N Eng J Med 357：1695-1704, 2006

8）Posner MR, et al：Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357：1705-1715, 2006

9）Pointreau Y, et al：Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Nat Cancer Inst 101：498-506, 2009

10）Janoray G, et al：Long-term results of a multicenter randomized phase Ⅲ trial of induction chemotherapy with cisplatin, 5-fluorouracil, ＋/− docetaxel for larynx preservation. J Natl Cancer Inst 108：djv368, 2016

11）Posner MR, et al：Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324：survival, surgery, and organ preservation. Ann Oncol 20：921-927, 2009

12）Argiris A, et al：Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 28：5294-5300, 2010

13）Zenda S, et al：A multicenter phase Ⅱ trial of docetaxel, cisplatin, and cetuximab（TPE）followed by cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck（ECRIPS study）. J Clin Oncol 35：6071, 2017

14）Dietz A, et al：Final results of the randomized phase Ⅱ DeLOS-Ⅱ trial；induction chemotherapy（IC）followed by radiotherapy（R）vs. cetuximab（E）plus IC and R for functional larynx preservation in resectable laryngeal and hypopharyngeal cancer（LHSCC）. J Clin Oncol 34：6025, 2016

15）Specenier PM, et al：TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin：a randomized phase Ⅱ EORTC trial. Ann Oncol 28：2219-2224, 2017

16）Gorphe P, et al：Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy. Laryngoscope 127：1791-1795, 2017

17）Budach W, et al：Induction chemotherapy followed by concurrent radio-chemotherapy versus radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck（HNSCC）；a meta-analysis of randomized trials. Radiother Oncol 118：238-243, 2016

18）Ghi MG, et al：Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase Ⅱ-Ⅲ trial. Ann Oncol 28：2206-2212, 2017